156 related articles for article (PubMed ID: 38612725)
1. The Predictive Role of Serum Lipid Levels, p53 and ki-67, According to Molecular Subtypes in Breast Cancer: A Randomized Clinical Study.
Faur IF; Dobrescu A; Clim IA; Pasca P; Prodan-Barbulescu C; Tarta C; Neamtu AA; Brebu D; Neamtu C; Rosu M; Duta C; Clim A; Lazar G; Totolici B
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612725
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients.
Chen R; Ye Y; Yang C; Peng Y; Zong B; Qu F; Tang Z; Wang Y; Su X; Li H; Yang G; Liu S
Breast Cancer Res Treat; 2018 Jul; 170(1):35-43. PubMed ID: 29480449
[TBL] [Abstract][Full Text] [Related]
3. P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients.
Pan Y; Yuan Y; Liu G; Wei Y
PLoS One; 2017; 12(2):e0172324. PubMed ID: 28235003
[TBL] [Abstract][Full Text] [Related]
4. Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response.
Diaz-Botero S; Espinosa-Bravo M; Gonçalves VR; Esgueva-Colmenarejo A; Peg V; Perez J; Cortes J; Rubio IT
Ann Surg Oncol; 2016 Nov; 23(12):3831-3837. PubMed ID: 27357178
[TBL] [Abstract][Full Text] [Related]
5. Association between systemic immune-inflammation index and neoadjuvant chemotherapy efficacy as well as prognosis in triple-negative breast cancer.
Pang J; Wang S; Liao L; Liu X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Sept 28; 46(9):958-965. PubMed ID: 34707005
[TBL] [Abstract][Full Text] [Related]
6. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
[TBL] [Abstract][Full Text] [Related]
7. HER2-positive is an independent indicator for predicting pathological complete response to neoadjuvant therapy and Ki67-changed after neoadjuvant chemotherapy predicts favorable prognosis in Chinese women with locally advanced breast cancer.
Fang Y; Zhang Q; Wu Y; Wu J
Medicine (Baltimore); 2024 Feb; 103(6):e37170. PubMed ID: 38335419
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.
Nishimura R; Osako T; Okumura Y; Hayashi M; Arima N
Breast Cancer; 2010 Oct; 17(4):269-75. PubMed ID: 19730975
[TBL] [Abstract][Full Text] [Related]
9. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
[TBL] [Abstract][Full Text] [Related]
10. Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer.
Kim T; Han W; Kim MK; Lee JW; Kim J; Ahn SK; Lee HB; Moon HG; Lee KH; Kim TY; Han SW; Im SA; Park IA; Kim JY; Noh DY
J Breast Cancer; 2015 Mar; 18(1):16-21. PubMed ID: 25834606
[TBL] [Abstract][Full Text] [Related]
11. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
12. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
13. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival.
Helal DS; Darwish SA; Awad RA; Ali DA; El-Guindy DM
Diagn Pathol; 2023 Feb; 18(1):11. PubMed ID: 36737799
[TBL] [Abstract][Full Text] [Related]
15. Distinguishing Low-Risk Luminal A Breast Cancer Subtypes with Ki-67 and p53 Is More Predictive of Long-Term Survival.
Lee SK; Bae SY; Lee JH; Lee HC; Yi H; Kil WH; Lee JE; Kim SW; Nam SJ
PLoS One; 2015; 10(8):e0124658. PubMed ID: 26241661
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
17. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis.
Keam B; Im SA; Lee KH; Han SW; Oh DY; Kim JH; Lee SH; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Bang YJ
Breast Cancer Res; 2011 Mar; 13(2):R22. PubMed ID: 21366896
[TBL] [Abstract][Full Text] [Related]
18. Impact of hormone receptor, HER2, and Ki-67 status conversions on survival after neoadjuvant chemotherapy in breast cancer patients: a retrospective study.
Chen Y; Liu X; Yu K; Sun X; Xu S; Qiu P; Lv Z; Zhang X; Guo A; Xu Y
Ann Transl Med; 2022 Jan; 10(2):93. PubMed ID: 35282081
[TBL] [Abstract][Full Text] [Related]
19. Correlations between serum lipid and Ki-67 levels in different breast cancer molecular subcategories.
Sun XB; Liu WW; Wang B; Yang ZP; Tang HZ; Lu S; Wang YY; Qu JX; Rao BQ
Oncol Lett; 2023 Feb; 25(2):53. PubMed ID: 36644143
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma.
Peng JH; Zhang X; Song JL; Ran L; Luo R; Li HY; Wang YH
Medicine (Baltimore); 2019 Jan; 98(2):e13554. PubMed ID: 30633152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
